equitymaster.comFalseFalseGSK PHARMA |
|
Price History |
Price | Rs | 1,943.1 | | % ch | % | 3.3 |
Mkt Cap | Rs m | 329,173 | | No. of
shares | m | 169.41 |
Vol | '000 | 18.7 | | % ch week | % | -2.9 |
P/E | X | 62.2 | | % ch 1-mth | % | -10.5 |
P/CF | X | 48.9 | | % ch 12-mth | % | 53.0 |
EPS (TTM) | Rs | 31.2 | | 52 week H/L | Rs | 2,650.0/1,228.0 |
(As on Mar 28, 2024 (Close)) |
|
Financials |
* Results Consolidated | No. of Months
Year Ending | 12
Mar-19* | 12
Mar-20* | 12
Mar-21* | 12
Mar-22* | 12
Mar-23* |
EQUITY SHARE DATA |
High | Rs | 3,595 | 1,745 | 1,805 | 1,917 | 1,684 |
Low | Rs | 1,253 | 1,046 | 1,155 | 1,400 | 1,231 |
Sales per share (Unadj.) | Rs | 184.6 | 190.3 | 172.7 | 193.5 | 191.9 |
Earnings per share (Unadj.) | Rs | 26.3 | 5.5 | 17.0 | 22.5 | 35.9 |
Diluted earnings per share | Rs | 26.3 | 5.5 | 17.0 | 22.5 | 35.9 |
Cash flow per share (Unadj.) | Rs | 29.2 | 10.4 | 21.6 | 26.5 | 39.8 |
Dividends per share (Unadj.) | Rs | 20.00 | 40.00 | 30.00 | 90.00 | 32.00 |
Adj. dividends per share | Rs | 20.00 | 40.00 | 30.00 | 90.00 | 32.00 |
Avg Dividend yield | % | 0.8 | 2.9 | 2.0 | 5.4 | 2.2 |
Book value per share (Unadj.) | Rs | 126.3 | 107.5 | 87.3 | 157.2 | 102.9 |
Adj. book value per share | Rs | 126.3 | 107.5 | 87.3 | 157.2 | 102.9 |
Shares outstanding (eoy) | m | 169.41 | 169.41 | 169.41 | 169.41 | 169.41 |
Bonus / Rights / Conversions | | 0 | 0 | 0 | 0 | 0 |
Price / Sales ratio | x | 13.1 | 7.3 | 8.6 | 8.6 | 7.6 |
Avg P/E ratio | x | 92.2 | 253.7 | 87.3 | 73.8 | 40.6 |
P/CF ratio (eoy) | x | 83.1 | 134.4 | 68.5 | 62.6 | 36.7 |
Price / Book Value ratio | x | 19.2 | 13.0 | 17.0 | 10.6 | 14.2 |
Dividend payout | % | 76.1 | 727.0 | 176.9 | 400.4 | 89.2 |
Avg Mkt Cap | Rs m | 410,644 | 236,440 | 250,695 | 280,960 | 246,858 |
No. of employees | `000 | NA | NA | NA | NA | NA |
Total wages/salary | Rs m | 5,372 | 6,286 | 6,162 | 6,102 | 5,950 |
Avg. sales/employee | Rs Th | 0 | 0 | 0 | 0 | 0 |
Avg. wages/employee | Rs Th | 0 | 0 | 0 | 0 | 0 |
Avg. net profit/employee | Rs Th | 0 | 0 | 0 | 0 | 0 |
INCOME DATA |
Net Sales | Rs m | 31,281 | 32,244 | 29,256 | 32,780 | 32,517 |
Other income | Rs m | 1,023 | 790 | 1,106 | 758 | 1,007 |
Total revenues | Rs m | 32,304 | 33,034 | 30,362 | 33,538 | 33,524 |
Gross profit | Rs m | 6,295 | 3,158 | 4,255 | 7,735 | 8,033 |
Depreciation | Rs m | 486 | 827 | 786 | 682 | 658 |
Interest | Rs m | 6 | 63 | 35 | 20 | 18 |
Profit before tax | Rs m | 6,827 | 3,058 | 4,540 | 7,790 | 8,364 |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 |
Tax | Rs m | 2,373 | 2,125 | 1,667 | 3,983 | 2,288 |
Profit after tax | Rs m | 4,454 | 932 | 2,873 | 3,808 | 6,076 |
Gross profit margin | % | 20.1 | 9.8 | 14.5 | 23.6 | 24.7 |
Effective tax rate | % | 34.8 | 69.5 | 36.7 | 51.1 | 27.4 |
Net profit margin | % | 14.2 | 2.9 | 9.8 | 11.6 | 18.7 |
BALANCE SHEET DATA |
Current assets | Rs m | 33,559 | 17,748 | 20,225 | 37,079 | 24,943 |
Current liabilities | Rs m | 28,041 | 10,220 | 13,546 | 16,984 | 13,264 |
Net working cap to sales | % | 17.6 | 23.3 | 22.8 | 61.3 | 35.9 |
Current ratio | x | 1.2 | 1.7 | 1.5 | 2.2 | 1.9 |
Inventory Days | Days | 351 | 42 | 51 | 91 | 97 |
Debtors Days | Days | 141 | 113 | 269 | 229 | 216 |
Net fixed assets | Rs m | 44,451 | 12,479 | 8,089 | 8,121 | 6,988 |
Share capital | Rs m | 1,694 | 1,694 | 1,694 | 1,694 | 1,694 |
"Free" reserves | Rs m | 19,704 | 16,512 | 13,089 | 24,936 | 15,735 |
Net worth | Rs m | 21,398 | 18,206 | 14,783 | 26,630 | 17,430 |
Long term debt | Rs m | 2 | 0 | 0 | 0 | 0 |
Total assets | Rs m | 78,043 | 30,227 | 30,115 | 45,201 | 31,930 |
Interest coverage | x | 1,233.3 | 49.3 | 129.6 | 391.3 | 462.6 |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 |
Sales to assets ratio | x | 0.4 | 1.1 | 1.0 | 0.7 | 1.0 |
Return on assets | % | 5.7 | 3.3 | 9.7 | 8.5 | 19.1 |
Return on equity | % | 20.8 | 5.1 | 19.4 | 14.3 | 34.9 |
Return on capital | % | 31.9 | 17.1 | 31.0 | 29.3 | 48.1 |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 |
Imports to sales | % | 22.7 | 27.1 | 39.0 | 27.0 | 48.1 |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 |
Imports (cif) | Rs m | 7,091 | 8,750 | 11,397 | 8,853 | 15,630 |
Fx inflow | Rs m | 534 | 276 | 278 | 528 | 1,622 |
Fx outflow | Rs m | 7,091 | 8,750 | 11,397 | 8,853 | 15,630 |
Net fx | Rs m | -6,557 | -8,474 | -11,119 | -8,325 | -14,008 |
CASH FLOW |
From Operations | Rs m | 4,095 | 4,905 | 5,779 | 8,107 | 4,842 |
From Investments | Rs m | -1,535 | -568 | 4,180 | -4,055 | 8,079 |
From Financial Activity | Rs m | -3,584 | -4,276 | -6,956 | -5,242 | -15,433 |
Net Cashflow | Rs m | -1,023 | 60 | 3,004 | -1,190 | -2,512 |
* Results Consolidated | Source: Company Annual Reports, Regulatory Filings, Equitymaster |
|
Share Holding |
Indian Promoters: | 0.0% |
Foreign collaborators: | 75.0% |
Indian inst/Mut Fund: | 11.6% |
FIIs: | 2.9% |
ADR/GDR: | 0.0% |
Free float: | 25.0% |
Shareholders: | 114,663 |
Pledged promoter(s) holding: | 0.0% |
|
Company Information |
REGD OFF: | Gsk House Dr. Annie Besant Road, Worli, Mumbai - 400030 |
E-MAIL: | in.investorquery@gsk.com |
WEB: | www.gsk-india.com |
TELEPHONE: | 022-24959595 |
FAX: | 022-24959494 |
SECTOR: | PHARMACEUTICALS |
GROUP: | Glaxo (F) Group |
TR AGENT: | K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.), Karvy Selenium Tower B Plot 31-32, Gachibowli Financial District, Nanakramguda |
AUDITOR: | Price Waterhouse & Co. |
CHM: | R S Karnad |
COMP SEC: | Ajay Nadkarni |
YEAR OF INC: | 1924 |
BSE CODE: | 500660 |
FV (Rs): | 10 |
DIV YIELD (%): | 1.6 |